Soluble guanylate cyclase stimulator attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2210
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Soluble guanylate cyclase stimulator attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs ; volume:5 ; number:1 ; day:16 ; month:6 ; year:2005 ; pages:1 ; date:6.2005
BMC pharmacology ; 5, Heft 1 (16.6.2005), 1, 6.2005
- Urheber
-
Evgenov, Oleg V.
Ichinose, Fumito
Evgenov, Natalia V.
Gnoth, Mark J.
Bloch, Kenneth D.
Zapol, Warren M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1471-2210-5-S1-S28
- URN
-
urn:nbn:de:101:1-2021081020344445841329
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Evgenov, Oleg V.
- Ichinose, Fumito
- Evgenov, Natalia V.
- Gnoth, Mark J.
- Bloch, Kenneth D.
- Zapol, Warren M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Inhaled and intravenous application of a stimulator of the soluble guanylate cyclase (BAY 41-8543) reduces pulmonary vascular resistance in a model of septic shock
sGC stimulators in experimental pulmonary hypertension
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
Inhaled NO and the guanylate cyclase stimulator Bay 41-2272 in oleic acid induced acute lung injury in rabbits
Awake Craniotomy for Cerebral Abscess with Pulmonary Arteriovenous Malformation
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension
A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation
Acute Pulmonary Toxicity and Body Distribution of Inhaled Metallic Silver Nanoparticles
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Activation of soluble guanylate cyclase reverses pulmonary vascular remodeling induced by hypoxia in mice
Inhaled and intravenous application of a stimulator of the soluble guanylate cyclase (BAY 41-8543) reduces pulmonary vascular resistance in a model of septic shock
sGC stimulators in experimental pulmonary hypertension
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
Inhaled NO and the guanylate cyclase stimulator Bay 41-2272 in oleic acid induced acute lung injury in rabbits
Awake Craniotomy for Cerebral Abscess with Pulmonary Arteriovenous Malformation
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension
A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation
Acute Pulmonary Toxicity and Body Distribution of Inhaled Metallic Silver Nanoparticles
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Activation of soluble guanylate cyclase reverses pulmonary vascular remodeling induced by hypoxia in mice
Inhaled and intravenous application of a stimulator of the soluble guanylate cyclase (BAY 41-8543) reduces pulmonary vascular resistance in a model of septic shock
sGC stimulators in experimental pulmonary hypertension
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
Inhaled NO and the guanylate cyclase stimulator Bay 41-2272 in oleic acid induced acute lung injury in rabbits
Awake Craniotomy for Cerebral Abscess with Pulmonary Arteriovenous Malformation
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension
A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation
Acute Pulmonary Toxicity and Body Distribution of Inhaled Metallic Silver Nanoparticles
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators